Literature DB >> 3264126

Pulmonary vascular permeability during the adult respiratory distress syndrome: a positron emission tomographic study.

F S Calandrino1, D J Anderson, M A Mintun, D P Schuster.   

Abstract

The natural history of change in pulmonary vascular permeability (PVP) during the adult respiratory distress syndrome (ARDS) is unknown. Therefore, we evaluated PVP by measuring the pulmonary transcapillary escape rate (PTCER) for transferrin with positron emission tomography (PET) in 15 ARDS patients, including 5 patients studied within 4 days of onset and 13 patients studied at least 7 days after onset. In 3 patients, studies were performed at both early and late stages. These results were compared to 12 non-smoking adult volunteers. Regional PTCER and extravascular lung density (EVD) were determined from a 1-h PET scan after intravenous injection of gallium-68 citrate, which binds rapidly to native transferrin. Oxygenation, radiologic score, as well as outcome were recorded for each patient. Mean PTCER was highest during the early phase of ARDS (560 +/- 275 x 10(-4) min-1) although PTCER in the late ARDS patients was also significantly higher than in normals (319 +/- 187 vs 58 +/- 33 x 10(-4) min-1; p less than .01). EVD was similar in both early and late ARDS groups (.39 +/- .08 and .37 +/- .13 g/ml lung, respectively) and markedly higher than in normals (.22 +/- .05 g/ml lung, p less than 0.01). PTCER decreased in each of the 3 serial studies. The correlation between PTCER and EVD was poor, as were correlations for either PTCER or EVD versus changes in oxygenation, radiologic score, survival, or duration of ventilator dependency. In the late ARDS patients, PTCER was usually elevated even if EVD had returned to normal.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3264126     DOI: 10.1164/ajrccm/138.2.421

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

1.  Measurement of protein flux with positron emission tomography in neonates.

Authors:  V Nama; J K Kozlowski; A Hamvas
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-01       Impact factor: 5.747

2.  The search for "objective" criteria of ARDS.

Authors:  Daniel P Schuster
Journal:  Intensive Care Med       Date:  2007-01-13       Impact factor: 17.440

3.  Losses of gallium in common laboratory ware and ways to minimize them.

Authors:  I Gonda; D L Swift
Journal:  Eur J Nucl Med       Date:  1991

4.  Synthesis and biodistribution of lipophilic and monocationic gallium radiopharmaceuticals derived from N,N'-bis(3-aminopropyl)-N,N'-dimethylethylenediamine: potential agents for PET myocardial imaging with 68Ga.

Authors:  Yui-May Hsiao; Carla J Mathias; Shiaw-Pyng Wey; Phillip E Fanwick; Mark A Green
Journal:  Nucl Med Biol       Date:  2009-01       Impact factor: 2.408

5.  Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans.

Authors:  Samir M Parikh; Tadanori Mammoto; Aylit Schultz; Hai-Tao Yuan; David Christiani; S Ananth Karumanchi; Vikas P Sukhatme
Journal:  PLoS Med       Date:  2006-03       Impact factor: 11.069

Review 6.  Purinergic signalling links mechanical breath profile and alveolar mechanics with the pro-inflammatory innate immune response causing ventilation-induced lung injury.

Authors:  Djo Hasan; Paul Blankman; Gary F Nieman
Journal:  Purinergic Signal       Date:  2017-05-26       Impact factor: 3.765

Review 7.  Recent advances in understanding acute respiratory distress syndrome.

Authors:  Peter Wohlrab; Felix Kraft; Verena Tretter; Roman Ullrich; Klaus Markstaller; Klaus Ulrich Klein
Journal:  F1000Res       Date:  2018-03-05

Review 8.  Pulmonary nuclear medicine.

Authors:  R F Miller; M J O'Doherty
Journal:  Eur J Nucl Med       Date:  1992

Review 9.  Endothelial pathomechanisms in acute lung injury.

Authors:  Nikolaos A Maniatis; Anastasia Kotanidou; John D Catravas; Stylianos E Orfanos
Journal:  Vascul Pharmacol       Date:  2008-07-29       Impact factor: 5.773

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.